Gene & Cell therapies have arrived, and bring with them important challenges. Our Task Force, including some of our members active in gene and cell therapies, have worked on a position paper addressing some important questions raised by these novel techniques. The paper sets out… read more
The German Ministry of Health recently released a draft bill proposal that would introduce significant changes to the legislation on Orphan Medicinal Products (OMPs) and biosimilars in Germany. The bill, which has yet to pass the Cabinet for approval, sets out plans for mandatory registries… read more
In a letter addressed to Martin Selmayr, European Commission Secretary General, the European health community – patients, researchers, pharmaceutical companies – raised its concerns about the lack of contingency measures specific to the continued collaboration on health and asks for an epxlicit commitment from both… read more
Following the last Medical Devices Coordination Group (MDCG)-Stakeholders’ meeting, the European Commission (EC) published a ‘Rolling Plan’containing the list of essential implementing acts and actions for the transitional period as well as information on expected timelines and state-of-play. As highlighted in the plan, the EC… read more
With the Brexit clock ticking, both sides are now preparing for a possible ’no deal’ Brexit, which could impact on patient and public health across the EU27. The European health community will express their concern that with time running out, no substantial progress has been… read more
The pharmaceutical industry represented by AESGP[1], EFPIA[2], EUCOPE[3], EuropaBio[4], Medicines for Europe and PPTA[5] – henceforth referred to as ‘the pharmaceutical industry’ – generally welcomes the European Commission (EC)’s Proposal for a Regulation on HTA[6]. We understand the scope of the joint clinical assessments foreseen… read more
On 13 March 2018, EUCOPE co-organised with Comitology.eu a breakfast discussion on “Future proofing EU policies for SMEs – a Case Study on Intellectual Property Rights”. Attended by over 30 commercial and institutional stakeholders as well as press and academia, the breakfast discussion touched upon… read more
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today responded to the European Council approving terms of the transition period agreed between the UK Government and EU. Statement… read more
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exiting the European Union. Abstract The… read more
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exiting the European Union. Today, organisations… read more
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter – the Innovation Eye-View